KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer. CE marking establishes that a diagnostic test meets the requirements of the European Medical Devices Directive, a necessary qualification step for commercialization of a diagnostic test in the European Union and other CE Mark territories.
KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer Test. This article is published at 01 July 2020 09:23 from Yahoo India Finance News Headlines, click on the read full article link below to see further details.
Diagnostics, Announces, Marking, Innovative, invasive, URO17™, Bladder, Cancer, Test